Skip to main content
    J

    Jaguar Animal Health Inc (JAGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    -0.03 (-7.74%)

    Market Cap: $5.59M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Jaguar Animal Health Inc (JAGX) Earnings: Report Dates and Results

    Updated Aug 19, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Jaguar Animal Health (JAGX) is expected to report earnings on Apr 5, 2027. In the quarter ended Jun 30, 2026, Jaguar Animal Health reported EPS of -$15.70, above the -$52.15 estimate. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    36%(12/33)
    Avg Surprise
    -47.48%
    Streak
    1 Q

    Next Report

    JAGX has an expected report date of Apr 5, 2027.

    JAGX Earnings Call

    The latest JAGX earnings call transcript on file is labeled 2025Q2.

    Read the 2025Q2 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, JAGX beat 16, missed 15 and matched 6. Revenue for the quarter ended Jun 30, 2026 was $1.23M, down 58.7% from $2.98M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$15.70-$52.15N/A+69.89%BeatN/AN/AN/AAug 19, 2026$1.23M
    Sep 30, 2025-$219.80-$177.80N/A-23.62%MissN/A11 up, 0 downNov 14, 2025$3.08M
    Jun 30, 2025-$259.26-$249.55N/A-3.89%MissN/A11 up, 0 downAug 14, 2025$2.98M
    Mar 31, 2025-$16.70-$10.82-$10.82 - -$10.82-54.34%MissN/A11 up, 0 downMay 15, 2025$2.21M
    Dec 31, 2024-$4,403.00-$647.50N/A-580.00%MissN/A11 up, 0 downMar 31, 2025$3.51M
    Sep 30, 2024-$918.75-$2,073.75N/A+55.70%BeatN/A10 up, 0 downNov 12, 2024$3.11M
    Jun 30, 2024-$3,535.00-$1,050.00N/A-236.67%MissN/A10 up, 0 downAug 12, 2024$2.72M
    Mar 31, 2024-$3,459.75-$1,575.00N/A-119.67%MissN/A10 up, 0 downApr 1, 2024$2.35M
    Dec 31, 2023-$33.00-$73.80N/A+55.28%BeatN/AN/A0 up, 0 downJan 31, 2024$2.30M
    Sep 30, 2023-$19,949.98-$64,574.94N/A+69.11%BeatN/AN/A0 up, 0 downNov 13, 2023$2.81M
    Jun 30, 2023-$36,224.96-$80,324.92N/A+54.90%BeatN/AN/AN/AAug 13, 2023$2.68M
    Mar 31, 2023-$125,474.87-$236,250.35N/A+46.89%BeatN/AN/A0 up, 0 downMay 15, 2023$1.97M
    Dec 31, 2022-$3.43-$9.75N/A+64.82%BeatN/AN/A0 up, 0 downMar 27, 2023$3.26M
    Sep 30, 2022-$472,500.71-$275,625.41-$314,844.31 - -$275,488.77-71.43%MissN/A20 up, 0 downNov 14, 2022$3.15M
    Jun 30, 2022-$472,500.71-$748,126.12N/A+36.84%BeatN/A10 up, 0 downAug 22, 2022$2.92M
    Mar 31, 2022-$1,000,000.00-$708,751.06N/A-41.09%MissN/A20 up, 0 downMay 10, 2022$2.63M
    Dec 31, 2021-$23.25-$6.75-$7.52 - -$6.02-244.44%MissN/A2N/AMar 11, 2022$2.08M
    Sep 30, 2021-$1,000,000.00-$787,501.18N/A-26.98%MissN/A2N/ANov 17, 2021$630000
    Jun 30, 2021-$1,000,000.00-$1,063,233.03N/A+5.95%BeatN/A2N/AAug 13, 2021$385000
    Mar 31, 2021-$1,000,000.00-$236,250.38N/A-323.28%MissN/A1N/AMay 17, 2021$1.24M
    Dec 31, 2020-$33.75-$22.50N/A-50.00%MissN/A1N/AMar 31, 2021$6.22M
    Sep 30, 2020-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A1N/ANov 16, 2020N/A
    Jun 30, 2020-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A2N/AAug 13, 2020$3.17M
    Mar 31, 2020-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A2N/AApr 3, 2020N/A
    Sep 30, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A2N/ANov 14, 2019$973000
    Jun 30, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In line-1428571528.4%1N/AAug 14, 2019$1.71M
    Mar 31, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AApr 10, 2019$1.59M
    Dec 31, 2018-$0.38-$0.07N/A-435.71%Miss-635.7%N/AN/AMar 13, 2019$1.60M
    Sep 30, 2018-$0.51-$0.45N/A-13.33%MissN/AN/AN/ANov 19, 2018$1.13M
    Jun 30, 2018$0.07-$0.45N/A+115.56%BeatN/AN/AN/AAug 13, 2018$883846
    Mar 31, 2018-$52.50-$0.60N/AN/AN/AN/AN/AN/AApr 9, 2018$804356
    Dec 31, 2017$0.07N/AN/AN/AN/AN/AN/AN/AMar 14, 2018$1.54M
    Sep 30, 2017-$63.00-$136.50N/A+53.85%BeatN/AN/AN/ANov 20, 2017$1.10M
    Jun 30, 2017-$126.00-$231.00N/A+45.45%BeatN/AN/AN/AAug 9, 2017$896521
    Mar 31, 2017-$5.00-$0.13N/AN/AN/AN/AN/AN/AMay 15, 2017$822410
    Dec 31, 2016-$294.00-$252.00N/A-16.67%MissN/AN/AN/AFeb 15, 2017$28877
    Sep 30, 2016-$315.00-$420.00N/A+25.00%BeatN/AN/AN/ANov 14, 2016$50357
    Jun 30, 2016-$367.50-$404.25N/A+9.09%BeatN/AN/AN/AAug 15, 2016$24143
    Mar 31, 2016-$451.50-$514.50N/A+12.24%BeatN/AN/AN/AMay 10, 2016$38146
    Dec 31, 2015-$441.00-$677.25N/A+34.88%BeatN/AN/AN/AMar 29, 2016$55186
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2024 was -$12,316.50, after -$181,682.81 the year before. It was -$1,871.19 for the year ended Dec 31, 2015, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2024-$12,316.50N/A
    Dec 31, 2023-$181,682.81N/A
    Dec 31, 2022-$1,945,004.85N/A
    Dec 31, 2021-$3,000,023.25N/A
    Dec 31, 2020-$6,000,033.75N/A
    Dec 31, 2018-$53.32N/A
    Dec 31, 2017-$193.93N/A
    Dec 31, 2016-$1,428.00N/A
    Dec 31, 2015-$1,871.19N/A

    Earnings Calls

    The 4 most recent earnings calls are listed below; the latest, 2025Q2 for the period ended Jun 30, 2025, runs about 3,400 words across 3 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q2Jun 30, 20253,4213
    2025Q1Mar 31, 20252,8664
    2024Q3Sep 30, 20245,2834
    2024Q2Jun 30, 20245,7315

    2025Q2 Earnings Call

    Opening remarks

    Lisa A. Conte CEO Thank you very much. Thank you for those introductory statements. Hello. Thank you for joining our webcast today. As you heard, my name is Lisa Conte. I am the Founder, President and CEO of Jaguar Health and our wholly owned subsidiary, Napo Pharmaceuticals. And I'm the Chairman of our Italian subsidiary, Napo Therapeutics. So as usual, if you've been on these webcasts before, I may use the words Jaguar and Napo interchangeably to refer to our company and our company activities. So as announced, this is an earnings webcast. And after I speak, our CFO, Carol Lizak, will provide a recap of the financial highlights for the second quarter of 2025. And as in the past, I am going to steal the thunder of Carol as we're pleased to report that our combined net second quarter 2025 revenue of approximately $3 million for prescription and nonprescription products, including license revenue, increased approximately 35% versus net Q1 2025, and it increased approximately 10% versus net Q2 2024. We're quite pleased with that. And to move along to the bigger picture for the company, 2025 continues to be the year of convergence of key clinical and regulatory catalysts for Jaguar. Catalysts that we feel will be transformative in terms of the value they bring to all the stakeholders in the company from patients, first and foremost, to our shareholders. Simply put, with the recent achievement of these catalysts, our strategy is to seek, and we are seeking business development partnerships for licensed rights to the development and commercialization of Jaguar's Human and Animal Health products with the goal of generating nondilutive funding for Jaguar. So important at this time of pullback and hopefully, temporary pullback of investor support for innovations in emerging pharma companies well beyond what we're seeing here at Jaguar. These catalysts are the key to those deals. To recap our recent catalysts, and may I comment that these remarkable, groundbreaking results are the culmination of years of regulatory and clinical planning activities and implementation, in some cases, up to eight years. And it just so happens that we have a convergence of critical catalysts at this time, again, in support of the opportunities for really important business development deals. On April 30 of this year, we released initial results from an independent investigator-initiated proof-of-concept study in pediatric patients in Abu Dhabi of a novel liquid formulation of crofelemer, our first-in-class plant-based paradigm-shifting prescription drug for intestinal failure associated with what we call microvillus inclusion disease, or MVID, which is an ultra-rare disease. And also intestinal failure associated with short bowel syndrome, SBS. For both these indications, crofelemer has orphan drug designation in the U.S.

    Frequently Asked Questions About JAGX

    When is Jaguar Animal Health's next earnings date?

    Jaguar Animal Health's next earnings report is expected for Apr 5, 2027.

    Did JAGX beat earnings estimates last quarter?

    Yes. Jaguar Animal Health reported EPS of -$15.70 for the quarter ended Jun 30, 2026, above the -$52.15 estimate, a 69.89% surprise.

    How often does JAGX beat earnings estimates?

    Jaguar Animal Health beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of -111.57%.